Description
The Naveni® CD8/MHC-I Atto647N is an in situ proximity ligation assay kit for the detection of the interaction of CD8 and MHC-I. This in situ kit gives a high signal-to-noise ratio and has outstanding specificity. The kit is compatible with immunofluorescence co-staining for visualization of the tumor microenvironment. The kit has been validated on FFPE human tissue samples. Not recommend for mouse tissue. For research use only. Not for use in diagnostic procedures.
The kit is built upon our Naveni® in situ proximity ligation technology, featuring two Navenibodies linked to proprietary oligo arms. This technology ensures precise and sensitive detection. The primary antibodies included in the kit bind to CD8 and MHC-I proteins, while Navenibodies then bind to their respective primary antibodies. When Navenibodies are in close proximity, a strong and distinct signal is generated, offering a specific and sensitive detection method for the interaction between CD8 and MHC-I.
Product code: PPI.TCR01.FR.100
Included in the kit:
- Primary antibody targeting human CD8 (Based on clone SP239 Abcam)
- Primary antibody targeting human MHC-I
- Two Navenibodies targeting respectively primary antibody
- Detection fluorophore Atto647N
- Buffers for blocking and dilutions and all detection reagents
- The Navenibody solution has a working volume of 4000µl (sufficient for approx. 100 reactions)
Not included in the kit:
- Tris EDTA antigen retrieval buffer pH 9
- Wash buffer
- DAPI nuclear stain
- Mounting medium
User instructions
Elucidate immune responses
Dive into the secrets of immune responses with our in situ proximity ligation assay for the detection of CD8/MHC-I interactions, providing a nuanced perspective for a detailed and accurate portrayal of the immune response. This deeper understanding becomes the cornerstone for developing targeted immunotherapies, marking a potential leap forward in precision medicine for cancer treatment. Cytotoxic CD8+ T-cells of the adaptive immune system are the most powerful effectors in the anticancer immune response and are the backbone of cancer immunotherapy. CD8+ T-cells recognize short peptide fragments displayed by major histocompatibility complex class I (MHC-I) molecules on the surface of antigen presenting cells and target cells. This specific peptide fragment binding is required for effective T-cell activation and triggers a range of critical immune protective effector functions against intracellular infections and malignancies.
Naveni® PPI
Proteins play a crucial role in various biological functions and serve as the most direct means of understanding biology. They are also pivotal targets in both maintaining health and addressing diseases. When proteins perform their functions, they engage with other proteins or molecules. To gain a deeper understanding of biological pathways and mechanisms, it is essential to delve into the functions of proteins and their interaction processes. Detecting these interactions has, up until the introduction of Naveni® Technology, been either complex, lacking specificity, or insensitive.
The Naveni® in situ proximity ligation technology now offers a solution for visualizing protein-protein interactions direct on sample slides, eliminating the need to disturb the tissue microenvironment.
Keywords: CD8/MHC-I, in situ proximity ligation assay, protein-protein interaction (PPI), in situ, bright-field, chromogenic, immunohistochemistry, western blot, validated antibodies, Immuno-oncology, immunotherapy, patient stratification, biomarker, drug-target engagement, tissue microenvironment, single-cell resolution, BRET, FRET, Co-IP.